Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Clinical Trial of MST-188 (purified poloxamer 188) Injection in Subjects with Sickle Cell Disease Experiencing Vaso-Occlusive Crisis

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2014
This article has no abstract
Epistemonikos ID: 0a5add9ec2b9f9dc20ee1e1783387cf648a6b952
First added on: Jan 22, 2025